Akorn (AKRX) Earning Somewhat Positive Media Coverage, Analysis Finds
Media stories about Akorn (NASDAQ:AKRX) have trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akorn earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0715656594514 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s analysis:
- Akorn, Inc. (AKRX) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Merck & (MRK) vs. Akorn (AKRX) Financial Survey (americanbankingnews.com)
- ETFs with exposure to Akorn, Inc. : November 17, 2017 (finance.yahoo.com)
- Akorn, Inc. (AKRX) Eye Catching Move in Focus- Alliant Energy Corporation (LNT) – Investing News Update (investingbizz.com)
Shares of Akorn (AKRX) remained flat at $$33.40 during mid-day trading on Monday. The stock had a trading volume of 1,090,432 shares, compared to its average volume of 2,747,689. The firm has a market cap of $4,180.00, a P/E ratio of 20.75, a price-to-earnings-growth ratio of 1.99 and a beta of 1.33. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. Akorn has a one year low of $17.61 and a one year high of $34.00.
AKRX has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Akorn from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Royal Bank Of Canada set a $34.00 price target on shares of Akorn and gave the company a “hold” rating in a research report on Sunday, July 30th. TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reissued a “hold” rating and set a $34.00 price target on shares of Akorn in a research report on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Akorn from a “hold” rating to a “strong sell” rating in a research report on Friday, August 25th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. Akorn currently has a consensus rating of “Hold” and a consensus target price of $29.38.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.